Naoto Ueno

Professor of Medicine

University of Hawai'i Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Naoto Ueno is a Professor of Medicine at the University of Hawai'i Cancer Center in the United States. His research areas focus on the therapeutic impacts and mechanisms in breast cancer, including studies on triple-negative breast cancer (TNBC), the tumor microenvironment, and the efficacy of novel treatment combinations. He has authored recent articles examining topics such as chemotherapy sensitization, immune reprogramming, and patient-reported outcomes in breast cancer therapies.

Articles (18)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (16)

Wendy Rathmell

Professor, Department Chair

Vanderbilt University Medical Center

UNITED STATES

Naoto Ueno

Research Interests

Explore related searches

Contact this professor

About

Articles (18)

Targeting CDK7 Enhances the Antitumor Efficacy of Enzalutamide in Androgen Receptor–Positive Triple-Negative Breast Cancer by Inhibiting c-MYC–mediated Tumorigenesis

Dual Therapeutic Impact of AXL Inhibitor AB-329: Chemotherapy Sensitization and Immune Microenvironment Reprogramming in TNBC

LMP7-Specific Inhibitor M3258 Modulates the Tumor Microenvironment of Triple-Negative Breast Cancer and Inflammatory Breast Cancer

Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC

Efficiency of Fulvestrant Monotherapy After CDK4/6 Inhibitor Exposure: Is This a Viable Choice?

ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors

Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes

Differences in Breast Cancer Subtypes among Racial/Ethnic Groups

Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines

Author Correction: Pan-cancer analysis of whole genomes.

Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial

Stabilization of E-cadherin adhesions by COX-2/GSK3β signaling is a targetable pathway in metastatic breast cancer

Phenotypic Plasticity in Circulating Tumor Cells Is Associated with Poor Response to Therapy in Metastatic Breast Cancer Patients

Comparison of the genomic alterations present in tumor samples from patients with metastatic inflammatory versus non-inflammatory breast cancer reveals AURKA as a potential treatment target

A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix<sup>®</sup> PC1 System

An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody–Drug Conjugates

NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis

Ensemble of nucleic acid absolute quantitation modules for copy number variation detection and RNA profiling

Collaborators (16)

Wendy Rathmell

Yu Shen

Lara Urban

Andrew Ewald

Toshiaki Iwase

Julie E. Lang

Bora Lim

Seong Gu Heo

Francisco G Rodriguez Gonzalez

Maxime Tarabichi

Elizabeth Mittendorf

Elizabeth Nakasone

Jangsoon Lee

Evan Cohen

Matthew Fittall

Samantha Bersani

Make your next move.